Golimumab for treating moderately to severely active ulcerative colitis in children aged 2 to 17 years

Golimumab is currently in clinical development for the treatment of moderately to severely active
ulcerative colitis (UC) among paediatric patients aged 2 to 17 years. UC is a long-term condition
where the colon and rectum become inflamed and small ulcers can develop on the colon's lining,
which may bleed and produce pus. Symptoms of UC include recurring diarrhoea, which may
contain blood, mucus or pus, stomach pain, needing to frequently empty bowels, fatigue, loss of
appetite and weight loss. The exact cause of UC is unknown, although it is thought to be the result
of a problem with the immune system. Treatment options for paediatric UC remain limited and
current modes of administration may be inconvenient for some patients.